Leerink Partnrs Brokers Lower Earnings Estimates for PRCT

PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) - Analysts at Leerink Partnrs lowered their Q1 2025 EPS estimates for shares of PROCEPT BioRobotics in a report released on Tuesday, February 25th. Leerink Partnrs analyst M. Kratky now expects that the company will earn ($0.47) per share for the quarter, down from their previous estimate of ($0.33). The consensus estimate for PROCEPT BioRobotics' current full-year earnings is ($1.75) per share. Leerink Partnrs also issued estimates for PROCEPT BioRobotics' Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($1.47) EPS, FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($0.57) EPS and FY2028 earnings at $0.03 EPS.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.01). The company had revenue of $68.24 million for the quarter, compared to analysts' expectations of $66.79 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%.

PRCT has been the topic of a number of other research reports. Truist Financial reaffirmed a "buy" rating and set a $90.00 target price (down previously from $105.00) on shares of PROCEPT BioRobotics in a research note on Wednesday, February 26th. Morgan Stanley cut their price objective on PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Jefferies Financial Group assumed coverage on PROCEPT BioRobotics in a research note on Thursday, November 14th. They issued a "hold" rating and a $95.00 target price on the stock. Finally, Wells Fargo & Company reissued an "overweight" rating and set a $112.00 target price on shares of PROCEPT BioRobotics in a research note on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, PROCEPT BioRobotics has an average rating of "Moderate Buy" and an average price target of $94.29.

Remove Ads

PROCEPT BioRobotics Trading Up 7.2 %

Shares of PRCT traded up $4.38 during midday trading on Friday, hitting $64.98. The stock had a trading volume of 1,873,684 shares, compared to its average volume of 953,062. The stock's 50 day moving average is $74.19 and its 200 day moving average is $80.04. The firm has a market cap of $3.39 billion, a PE ratio of -33.32 and a beta of 1.03. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07. PROCEPT BioRobotics has a 1 year low of $45.56 and a 1 year high of $103.81.

Insider Transactions at PROCEPT BioRobotics

In related news, CEO Reza Zadno sold 26,423 shares of the stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $97.22, for a total transaction of $2,568,844.06. Following the completion of the sale, the chief executive officer now owns 152,762 shares of the company's stock, valued at $14,851,521.64. This represents a 14.75 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Alaleh Nouri sold 28,092 shares of the firm's stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $97.13, for a total transaction of $2,728,575.96. Following the completion of the sale, the executive vice president now owns 52,472 shares of the company's stock, valued at approximately $5,096,605.36. This trade represents a 34.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 17.40% of the company's stock.

Institutional Investors Weigh In On PROCEPT BioRobotics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Westfield Capital Management Co. LP purchased a new position in shares of PROCEPT BioRobotics in the 3rd quarter valued at approximately $72,563,000. FMR LLC increased its stake in PROCEPT BioRobotics by 11.9% during the 4th quarter. FMR LLC now owns 8,159,208 shares of the company's stock valued at $656,979,000 after purchasing an additional 866,328 shares in the last quarter. Perpetual Ltd purchased a new position in shares of PROCEPT BioRobotics in the fourth quarter worth $66,972,000. Wellington Management Group LLP lifted its stake in shares of PROCEPT BioRobotics by 38.8% during the fourth quarter. Wellington Management Group LLP now owns 1,490,952 shares of the company's stock worth $120,051,000 after buying an additional 416,819 shares during the period. Finally, Franklin Resources Inc. grew its holdings in shares of PROCEPT BioRobotics by 64.5% during the third quarter. Franklin Resources Inc. now owns 885,992 shares of the company's stock valued at $64,669,000 after buying an additional 347,330 shares during the last quarter. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).